AEON Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEON research report →
Price Chart
About the company
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis.
- CEO
- Robert Bancroft
- IPO
- 2023
- Employees
- 8
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on AEON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.13M
- P/E
- -0.04
- Fwd P/E
- 1.42
- PEG
- 0.01
- P/S
- 0.00
- P/B
- -0.61
- EV/EBITDA
- -0.29
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 204.18%
- ROIC
- 1699.74%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-12,803,000
- Net Income
- $-39,222,000-193.4%
- EPS
- $-3.95-105.1%
- OCF Growth
- +14.7%
- FCF Growth
- +14.7%
- 52W High
- $1.45
- 52W Low
- $0.18
- 50D MA
- $0.46
- 200D MA
- $0.85
- Beta
- 0.64
- RSI (14)
- 20
- Avg Volume
- 1.72M
No earnings-call transcripts are available for AEON yet.
- Free Float
- 27.4%
- Shares Outstanding
- 44.16M
- Float Shares
- 12.10M
of shares held by institutions
22 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 100.33K | ▲ 1.76K |
| Cibc Private Wealth Group, LLC | 33 | 0 |
Held by 6 ETFs
Biggest fund positions in AEON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 17, 26 | Thunen Shelley B | other | 222,684 |
| Jun 17, 26 | PALMISANO ROBERT J | other | 222,684 |
| Jun 17, 26 | Forth Marc | other | 222,684 |
| Jun 17, 26 | FISCHER JOST | other | 222,684 |
| Jun 17, 26 | Carter Eric G | other | 222,684 |
| Apr 2, 26 | Bencich John | other | 754,717 |
| Apr 1, 26 | Bencich John | other | 0 |
| Mar 4, 26 | Oh Chad | other | 1,316,872 |
| Feb 17, 26 | Oh Chad | other | 862,500 |
| Mar 4, 26 | Wilson Alexander Blair | other | 1,316,872 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AEON coverage
Recent articles, reports, and earnings notes.
No research on AEON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AEON report →AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX®
globenewswire.com · Aug 19
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 12
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
globenewswire.com · Aug 3
Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards
globenewswire.com · Jul 27
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
globenewswire.com · Jul 14
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
globenewswire.com · Jun 4
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 14
AEON Biopharma Sets Annual Shareholder Meeting
globenewswire.com · Apr 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.